Wynik wyszukiwania w bazie Polska Bibliografia Lekarska GBL

Zapytanie: PERETZ
Liczba odnalezionych rekordów: 1



Przejście do opcji zmiany formatu | Wyświetlenie wyników w wersji do druku
1/1

Tytuł oryginału: Ethical issues in molecular epidemiology.
Autorzy: Richter Elihu D., Peretz Tamar
Źródło: Prz. Epidemiol. 2002: 56 supl.: Conference on molecular epidemiology in preventive medicine - achievements and new challenges s.355-368, il., tab., bibliogr. 24 poz. - Konferencja pt. Molekularna epidemiologia w medycynie prewencyjnej - osiągnięcia i nowe wyzwania Kraków 20-22.06. 2002
Sygnatura GBL: 301,250

Hasła klasyfikacyjne GBL:
  • genetyka

    Typ dokumentu:
  • praca związana ze zjazdem
  • tytuł obcojęzyczny

    Wskaźnik treści:
  • ludzie

    Streszczenie angielskie: New developments in Molecular Epidemiology make it possible to (1) identify groups at excess group risk for cancer from exposures to carcinogens; (2) identify individuals at special risk from genetic susceptibility (3) identify subgroups at special individual risks for adverse health effects from exposures to toxic agents; and (4) assess the role of interventions in reducing the risks for these effects (e.g. reduction in clastogenic changes as a maarker of nutritional modification of effects from exposure to ionizing radiation). They also hold the promise of providing information on specificity on dose-response relationships in medico-legal assessments for elligibility for compensation. The use of biomarkers in the assessment of the benefits of community-based interventions is especially promising. This paper presents case studies which exame some of the ethical questions arising from the emergence of molecular epidemiology. Will new data from molecular epidemiology promote or dilute new concepts of protection based on the precautionary principle? In occupational medicine, will biomarkers be used to identify new genetic sub castes whose members will be targeted for removal from the work environment, on grounds of cost-benefit? In population-cohorts, e.g. individuals with past high exposures to hazardous agents, does knowledge coming from use of biomarkers for early detection on early sings of potential risk in groups justify monitoring if there are no known benefits to the individual from early detection?...

    stosując format: